[go: up one dir, main page]

WO1993001820A3 - Inhibition de l'infection hiv a mediation par la proteine non-cd4 - Google Patents

Inhibition de l'infection hiv a mediation par la proteine non-cd4 Download PDF

Info

Publication number
WO1993001820A3
WO1993001820A3 PCT/US1992/005985 US9205985W WO9301820A3 WO 1993001820 A3 WO1993001820 A3 WO 1993001820A3 US 9205985 W US9205985 W US 9205985W WO 9301820 A3 WO9301820 A3 WO 9301820A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv infection
inhibition
mediated hiv
hiv
methods
Prior art date
Application number
PCT/US1992/005985
Other languages
English (en)
Other versions
WO1993001820A2 (fr
Inventor
Benson M Curtis
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of WO1993001820A2 publication Critical patent/WO1993001820A2/fr
Publication of WO1993001820A3 publication Critical patent/WO1993001820A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)

Abstract

On a isolé un récepteur non CD4-gp120 spécifique possédant une affinité de liaison spécifique envers la protéine de surface gp120 présente dans le virus du syndrome immunodéficitaire acquis (HIV). On décrit des méthodes de traitement de l'infection HIV dans les cellules négatives CD4, telles que celles du côlon et du cerveau, ainsi que des procédés de détection de l'HIV et des trousses diagnostic.
PCT/US1992/005985 1991-07-16 1992-07-16 Inhibition de l'infection hiv a mediation par la proteine non-cd4 WO1993001820A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73121491A 1991-07-16 1991-07-16
US731,214 1991-07-16

Publications (2)

Publication Number Publication Date
WO1993001820A2 WO1993001820A2 (fr) 1993-02-04
WO1993001820A3 true WO1993001820A3 (fr) 1993-05-27

Family

ID=24938578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/005985 WO1993001820A2 (fr) 1991-07-16 1992-07-16 Inhibition de l'infection hiv a mediation par la proteine non-cd4

Country Status (7)

Country Link
AU (1) AU2373792A (fr)
IE (1) IE922308A1 (fr)
IL (1) IL102508A0 (fr)
MX (1) MX9204131A (fr)
PT (1) PT100694A (fr)
WO (1) WO1993001820A2 (fr)
ZA (1) ZA925305B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2748483B1 (fr) * 1996-05-07 1998-07-24 Orstom Moyens pour la lutte ou le diagnostic d'une infection par hiv
WO1996041884A1 (fr) * 1995-06-09 1996-12-27 Institut Français De Recherche Scientifique Pour Le Developpement En Cooperation (Orstom) MOYEN POUR DETECTER ET PREVENIR UNE INFECTION A VIH, FAISANT APPEL A DES RECEPTEURS OU A DES SITES DE FIXATION CAPABLES D'INTERAGIR AVEC gp120
EP1046651A1 (fr) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition et méthode pour moduler l'interaction des cellules dendritiques et les cellules T
AUPQ278899A0 (en) * 1999-09-13 1999-10-07 Csl Limited Dendritic cell membrane protein cire
US7541032B2 (en) 2002-09-20 2009-06-02 Stichting Katholieke Universiteit Antigen uptake receptor for Candida albicans on dendritic cells
AU2003278541A1 (en) 2002-09-20 2004-04-08 Stichting Katholieke Universiteit Method of treating rheumatoid arthritis by interfering with expression of dc-sign by macrophages and diagnosis thereof
DE60327237D1 (de) 2002-11-05 2009-05-28 Pasteur Institut Dc-sign blockern und deren verwendung zur vorbeugung oder behandlung von viraleninfektionen
US7427469B2 (en) 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
CA2549800A1 (fr) 2003-12-15 2005-06-30 Alexion Pharmaceuticals, Inc. Nouveaux anticorps anti-dc-sign
WO2006055711A1 (fr) * 2004-11-18 2006-05-26 Kent Hann Composition contenant un isolat d'aloe vera et un prebiotique synergique et leur application therapeutique
GB0702183D0 (en) * 2007-02-05 2007-03-14 Iti Scotland Ltd Pathogen binding

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AIDS vol. 3, no. 12, 1989, pages 793 - 798 LARKIN. M. ET AL.; 'Oligosaccharide-mediated interactions of the envelope glycoprotein gp120 of HIV-1 that are independent of CD4 recognition"' cited in the application *
BULL. INST. PASTEUR vol. 89, no. 2, June 1991, IZRACHI, Y. ET AL.; 'Efficient binding , fusion and entry of HIV1 into CD4 negative neural cells : a mechanism for neuropathogenesis in Aids.' *
JOURNAL OF MEDICAL VIROLOGY vol. 35, no. 3, November 1991, pages 187 - 191 MORRISSON, N.K. ET AL.; 'Growth of human immunodeficiency virus 1 in cultured cells in the absence of the CD4 antigen."' *
NATURE. vol. 337, 1989, LONDON GB pages 368 - 370 CLAPHAM, P.R. ET AL.; 'Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells.' cited in the application *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 89, September 1992, WASHINGTON US pages 8356 - 8360 Curtis, Benson M.; Scharnowske, S.; Watson, A.J.; 'Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120.' *
THE JOURNAL OF EXPERIMENTAL MEDECINE vol. 169, January 1989, THE ROCKEFELLER UNIV. PRESS pages 185 - 196 EZEKOWITZ, R.A.B. ET AL.; 'A human serum mannose binding protein inhibits in vitro infection by the human immunodeficeincy virus.' *

Also Published As

Publication number Publication date
PT100694A (pt) 1993-10-29
ZA925305B (en) 1993-06-14
AU2373792A (en) 1993-02-23
IE922308A1 (en) 1993-01-27
MX9204131A (es) 1993-04-01
IL102508A0 (en) 1993-01-14
WO1993001820A2 (fr) 1993-02-04

Similar Documents

Publication Publication Date Title
WO1988009181A3 (fr) Anticorps monoclonaux neutralisant le hiv-1
EP0887427A3 (fr) Amplification et détection du HIV-1 et/or HIV-2
CA2082948A1 (fr) Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4
CA2107732A1 (fr) Retrovirus du groupe vih et son utilisation
WO1993001820A3 (fr) Inhibition de l'infection hiv a mediation par la proteine non-cd4
CA2143163A1 (fr) Peptides derives d'un retrovirus du groupe vih et leur utilisation
EP1026263A3 (fr) Amorces oligonucleotides pour la transkription inverse pour la detection efficace d'hiv-1 et hiv-2 et leurs usages
AUPO784197A0 (en) Treatment of nasopharyngeal carcinoma
AU8083594A (en) Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
EP0891982A3 (fr) Peptides de VIH
DK0479909T3 (da) Bispecifikke reagenser til AIDS-behandling
CA2363947A1 (fr) Peptides, antigenes du vih, compositions de vaccins afferentes, trousse de dosage immunologique et methode de detection d'anticorps induits par le vih
CA2082825A1 (fr) Inhibition de l'infection virale
CA2169603A1 (fr) Retrovirus du groupe vih et son utilisation
WO1991015512A3 (fr) Polypeptides d'enveloppe du vih
EP0306219A3 (fr) Protéines et peptides du HIV pour le diagnostic, la prophylaxie et la thérapie du SIDA
AU2567888A (en) Hiv peptides and methods for detection of hiv
WO1990013281A3 (fr) Procede de suppression d'une infection par l'hiv
WO1998038325A3 (fr) Vecteurs retroviraux, leur procede de production et leur utilisation pour le transfert genique dans des cellules positives cd-4
EP0323157A3 (fr) Composés antiviraux et méthodes
CA2131087A1 (fr) Souches de streptomyces et methodes produisant selectivement une seule composante d'une streptogramine
EP0311108A3 (fr) Azido 3'-diamino-2,6-purine-didéoxy,2',3'-ribosides actifs contre HIV
AU5061090A (en) Aids therapy
AU2530795A (en) Assay for hiv-1 group o using at least one gp41 peptide
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA